Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias
Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Par...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2016-02-01
|
| Series: | Case Reports in Neurology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/444278 |
| _version_ | 1828484221659774976 |
|---|---|
| author | Scott J. Sherman Miguel Estevez Ari B. Magill Torsten Falk |
| author_facet | Scott J. Sherman Miguel Estevez Ari B. Magill Torsten Falk |
| author_sort | Scott J. Sherman |
| collection | DOAJ |
| description | Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to reduce L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression. Based on the literature we hypothesize that low-dose ketamine may act as a ‘chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity, including in the basal ganglia and the motor cortex. The presented PD case reports indicate tolerability, safety and long-term beneficial effects of low-dose ketamine infusion that should be further investigated in a properly controlled prospective clinical trial for treatment of LID, as well as the prevalent nonmotor features pain and depression in PD patients. |
| first_indexed | 2024-12-11T08:52:01Z |
| format | Article |
| id | doaj.art-e57975e55aa64492aaab964794d0c310 |
| institution | Directory Open Access Journal |
| issn | 1662-680X |
| language | English |
| last_indexed | 2024-12-11T08:52:01Z |
| publishDate | 2016-02-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Neurology |
| spelling | doaj.art-e57975e55aa64492aaab964794d0c3102022-12-22T01:14:00ZengKarger PublishersCase Reports in Neurology1662-680X2016-02-0181535810.1159/000444278444278Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced DyskinesiasScott J. ShermanMiguel EstevezAri B. MagillTorsten FalkKetamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to reduce L-DOPA-induced dyskinesia (LID), improve on time, and reduce depression. Based on the literature we hypothesize that low-dose ketamine may act as a ‘chemical deep brain stimulation', by desynchronizing hypersynchronous oscillatory brain activity, including in the basal ganglia and the motor cortex. The presented PD case reports indicate tolerability, safety and long-term beneficial effects of low-dose ketamine infusion that should be further investigated in a properly controlled prospective clinical trial for treatment of LID, as well as the prevalent nonmotor features pain and depression in PD patients.http://www.karger.com/Article/FullText/444278Parkinson’s diseaseDepressionPainHypersynchronyNMDA receptorsLevodopa |
| spellingShingle | Scott J. Sherman Miguel Estevez Ari B. Magill Torsten Falk Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias Case Reports in Neurology Parkinson’s disease Depression Pain Hypersynchrony NMDA receptors Levodopa |
| title | Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias |
| title_full | Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias |
| title_fullStr | Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias |
| title_full_unstemmed | Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias |
| title_short | Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing L-DOPA-Induced Dyskinesias |
| title_sort | case reports showing a long term effect of subanesthetic ketamine infusion in reducing l dopa induced dyskinesias |
| topic | Parkinson’s disease Depression Pain Hypersynchrony NMDA receptors Levodopa |
| url | http://www.karger.com/Article/FullText/444278 |
| work_keys_str_mv | AT scottjsherman casereportsshowingalongtermeffectofsubanestheticketamineinfusioninreducingldopainduceddyskinesias AT miguelestevez casereportsshowingalongtermeffectofsubanestheticketamineinfusioninreducingldopainduceddyskinesias AT aribmagill casereportsshowingalongtermeffectofsubanestheticketamineinfusioninreducingldopainduceddyskinesias AT torstenfalk casereportsshowingalongtermeffectofsubanestheticketamineinfusioninreducingldopainduceddyskinesias |